Date: prev next · Thread: first prev next last
2012 Archives by date, by thread · List index


Hi,

webmaster-Kracked_P_P wrote (03-06-12 15:55)

As the original poster of the User thread on this subject, I want to
step in and give you my opinion.

Thanks for doing so.
Additionally: just numbers say so little.
Even a regression may not be a problem, when compared to improvements over previous versions.
Don't understand me wrong and think that I'm fully happy with the situation.
However, it is up to the individual company (and supporting consultant) to decide which version is best for them. Really I know larger deployments moving to 3.5.1 already because of the improvements over the 3.4-line. Does that mean that it's better for all? No, of course not. Still I regret that I'm not able to spend some more time currently, cause for sure clearer categorizing of issues/regressions would make it easier to judge both individual and the global situation. And some more of that ;-)

Kind regards,

--
 - Cor
 - http://nl.libreoffice.org


--
Unsubscribe instructions: E-mail to marketing+help@global.libreoffice.org
Problems? http://www.libreoffice.org/get-help/mailing-lists/how-to-unsubscribe/
Posting guidelines + more: http://wiki.documentfoundation.org/Netiquette
List archive: http://listarchives.libreoffice.org/global/marketing/
All messages sent to this list will be publicly archived and cannot be deleted

Context


Privacy Policy | Impressum (Legal Info) | Copyright information: Unless otherwise specified, all text and images on this website are licensed under the Creative Commons Attribution-Share Alike 3.0 License. This does not include the source code of LibreOffice, which is licensed under the Mozilla Public License (MPLv2). "LibreOffice" and "The Document Foundation" are registered trademarks of their corresponding registered owners or are in actual use as trademarks in one or more countries. Their respective logos and icons are also subject to international copyright laws. Use thereof is explained in our trademark policy.